StockData

Universe Pharmaceuticals INC (UPC) company profile

UPCNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Sep 30, 2025Last filing: 20-F on Jan 29, 2026Score 5/30
$1.56+0.08 (+5.41%)

Close on Nov 17, 2026Market cap $878.81KP/E –Yield –

About Universe Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Universe Pharmaceuticals INC is a Cayman Islands holding company that operates through its subsidiaries in China, primarily Jiangxi Universe Pharmaceuticals Co., Ltd. and its operating entities. The company engages in the traditional Chinese medicine (TCM) and traditional Chinese medicine derivatives (TCMD) business sectors, with dedicated research and commercial trading arms such as Guangzhou Universe Hanhe Medical Research Co., Ltd. and Jiangxi Universe Pharmaceuticals Trade Co., Ltd.

The company's operations and operating entities are located entirely within the People's Republic of China, with principal executive offices situated in Ji'an, Jiangxi Province. As a holding vehicle, the entity maintains an international intermediate structure through Universe Pharmaceuticals Group (International) Limited in Hong Kong, which directly owns its PRC-based management entity, Jiangxi Universe Pharmaceuticals Technology Co., Ltd.

Summary of the business section of Universe Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Universe Pharmaceuticals INC
Founded
2010
Headquarters
Ji'An, Jiangxi, F4
Address
265 Jingjiu Avenue, Jinggangshan Econ. And Tech. Dev. Zone 343100
Phone
86-0796-8403309
Employees
225, Sep 30, 2025
Industry
Pharmaceutical Preparations
Incorporated in
F4
Fiscal year ends
September 30
Auditor
Enrome LLP, Singapore

Stock & identifiers

Ticker
UPC
Exchange
Nasdaq
IPO date
Mar 24, 2021
Shares outstanding
1M, Sep 30, 2025
Filer category
Non-accelerated filer<br>Emerging growth company
Stock splits
1-for-600 reverse, Apr 29, 2025; 1-for-40 reverse, Mar 24, 2025; 1-for-15 reverse, Nov 18, 2024; 1-for-6 reverse, Jul 28, 2023
SEC CIK
1809616
CUSIP
G9442G138
FIGI
BBG00WRF65K6
Share class FIGI
BBG00WRF66B4
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Gang LaiChief Executive Officer, Director87,967
Lin (Lydia) YangChief Financial Officer, Director–
Baochang LiuChief Operating Officer–
Jiawen PangDirector–
Yongping YuDirector–
Ding ZhengDirector–

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 24, 2021
Offer price
$5.00
Exchange
Nasdaq
First trading day
Mar 23, 2021
First-day close
$4.75-5.0%
Lock-up ends (est.)
Sep 19, 2021

“ed Company.” Per Share Total Initial public offering price (1) $ 5.00 $ 25,000,000 Underwriter’s discounts (2) $ 0.255 $ 1,275,000 Proceeds to our company before expenses (3) $ 4.745 $ 23,725,000 (1) Initial public offering price per share is $5.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of September 30, 2025, 2024 and 2023, we had a total of 216, 225 and 225 employees, all of whom are located in China.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?